Evidence map›Paper›PMID 29681184›Full record

ArticleIntegrative cancer therapies2018

TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer.

Feng-Jiao Wang, Peng Wang, Lian-Yu Chen, Ya-Wen Geng, Hao Chen, Zhi-Qiang Meng, Lu-Ming Liu, Zhen Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Feng-Jiao Wang1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Peng Wang1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Lian-Yu Chen1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Ya-Wen Geng1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Hao Chen1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Zhi-Qiang Meng1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Lu-Ming Liu1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Zhen Chen1 Department of Integrative Oncology, Fudan University, Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSyndrome ( ZHENG in Chinese) in traditional Chinese medicine (TCM) refers to the intrinsic characteristics of a pathological process at a certain stage; these characteristics are influenced by internal and external environments and reveal the nature of a disease. Proper syndrome differentiation is the basic principle that guides clinical treatment.

objectiveTo have a good understanding of tumor progression and the different mechanisms related to ZHENG that have occurred before and after tumor development and to explore the valid evaluation criteria of different pancreatic cancer syndromes to improve the guiding role of TCM syndrome differentiation in pancreatic cancer treatment.

methodsIn this study, we established mouse subcutaneous pancreatic cancer models, namely, Con (control), Pi-Xu (Spleen-Deficiency), Shi-Re (Dampness-Heat), and Xue-Yu (Blood-Stasis). Then, for the first time, we compared the different effects of " ZHENG-first" (referring to a different disease status that occurred before tumor occurrence) and "Tumor-first" (referring to the change in the tumor microenvironment and the resulting changes in the state of the body) conditions on tumor progression and evaluated the associated molecular mechanisms.

resultsWe found that tumor growth in the " ZHENG-first" and "Tumor-first" conditions was different. In the "Tumor-first" model, the tumor growth in the Pi-Xu group was faster than that in the other groups. However, in the " ZHENG-first" model, the tumor growth trend was most obvious in the Shi-Re group. There was a difference in tumor-associated macrophage infiltration between the 2 models. The expression levels of the inflammatory cytokines IL-6, IL-10, and P-STAT3 were also differentially altered.

conclusionThe emergence of ZHENG conditions before or after tumor occurrence had different impacts on pancreatic cancer development, and these impacts may be related to differences in tumor-associated macrophage infiltration and the involved inflammatory cytokines IL-6, IL-10, and P-STAT3. The study results uncovered the molecular basis of syndrome differentiation in pancreatic cancer progression, which might provide more specific guidance for TCM treatment of pancreatic cancer.

Indexed as

AnimalsCell DifferentiationCell ProliferationDisease Models, AnimalDisease ProgressionFemaleInflammationInterleukin-10Interleukin-6MacrophagesMiceMice, Inbred C57BLPancreatic NeoplasmsSTAT3 Transcription FactorInterleukin-10Interleukin-6STAT3 Transcription Factorinflammatory cytokinespancreatic cancersyndromeTAMTCMtraditional Chinese medicineZHENG

Identifiers

PMID29681184
PMCPMC6142096
OpenAlexW2801850397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.